Shohei Koyama (Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine), Atsushi Kumanogoh (Osaka University Graduate School of Medicine & IFReC), and their research group developed a method for monitoring the state of anti-PD-1 antibody binding to T lymphocytes. They found nivolumab bounds to T lymphocytes for more than 20 weeks even after the last infusion.

The change in nivolumab-binding status.
The schematics present three different binding statuses: complete binding, partial binding, and no binding.

Commentary(PDF)


Article (External-Link)

Contact:

Atsushi Kumanogoh（Immunopathology）

06-6879-3831
kumanogoimed3.med.osaka-u.ac.jp

Immunology Frontier Research Center, Osaka University (WPI-IFReC)